Limits...
Matrine Exerts a Strong Anti-Arthritic Effect on Type II Collagen-Induced Arthritis in Rats by Inhibiting Inflammatory Responses

View Article: PubMed Central - PubMed

ABSTRACT

To investigate anti-arthritic effects of matrine isolated from the roots of S. flavescens on type II collagen-induced arthritis (CIA) in rats and to explore its related potential mechanisms, CIA rats were established and administered with matrine (20, 40 or 80 mg/kg/days, for 30 days). Subsequently, blood was collected to determine serum levels of TNF-α, IL-1β, IL-6, IL-8, IL-17A, IL-10, MMP-2, MMP-3 and MMP-9, and hind paws and knee joints were collected for histopathological examination. Furthermore, indices of the thymus and spleen were determined, and synovial tissues were collected to determine the protein expressions of p-IκB, IκB, Cox-2 and iNOS. Our results indicated that matrine significantly suppressed inflammatory reactions and synovial tissue destruction. Matrine inhibited paw swelling, arthritis indices and weight loss in CIA rats. Additionally, matrine decreased the levels of TNF-α, IL-1β, IL-6, IL-8, IL-17A, MMP-2, MMP-3 and MMP-9. Matrine also down-regulated expressions of p-IκB, Cox-2, and iNOS but up-regulated IκB in synovial tissues in CIA rats. The results suggested matrine possesses an anti-arthritic effect in CIA rats via inhibiting the release of pro-inflammatory cytokines and proteins that promote the NF-κB pathway.

No MeSH data available.


Related in: MedlinePlus

Effects of matrine on arthritis score changes for the paw of CIA rats. Norm: normal rats; Cont: control rats; Dex: rats treated with dexamethasone. Data are presented as the mean ± SD (n = 10). * p < 0.05, ** p < 0.01, compared with Cont. (control). Day 0 in the figure is day 21 after initial immunization.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5037690&req=5

ijms-17-01410-f002: Effects of matrine on arthritis score changes for the paw of CIA rats. Norm: normal rats; Cont: control rats; Dex: rats treated with dexamethasone. Data are presented as the mean ± SD (n = 10). * p < 0.05, ** p < 0.01, compared with Cont. (control). Day 0 in the figure is day 21 after initial immunization.

Mentions: A type II collagen-induced arthritis (CIA) rat model was prepared to evaluate the therapeutic effects of matrine in rats with RA. As shown in Figure 1, Figure 2 and Figure 3, compared with the normal rats, significant RA symptoms were observed when the experimental rats were immunized with type II collagen (CII) twice, including paw swelling and erythema (p < 0.01), higher arthritis indices (p < 0.01) and obvious weight loss (p < 0.05). These symptoms significantly improved after treatment with dexamethasone. Our results indicate that starting on the 6th day after the initial dexamethasone administration (0.05 mg/kg), paw swelling was decreased in CIA rats compared with the control group (p < 0.01) (Figure 1). Additionally, the arthritis indices in the dexamethasone (0.05 mg/kg)-treated CIA rats were also significantly decreased compared with the control group (p < 0.01) (Figure 2). However, it was clear that the daily administration of dexamethasone (0.05 mg/kg) did not reverse the body weight loss observed in the CIA rats; instead, dexamethasone aggravated the weight loss (Figure 3). This effect might be associated with the inherent side effects of dexamethasone. Similar to the dexamethasone treatment, matrine significantly decreased paw swelling and arthritis indices when administered at doses of 40 (p < 0.05) and 80 mg/kg (p < 0.01), and matrine moderately decreased these symptoms when administered daily at a dose of 20 mg/kg (Figure 1 and Figure 2). Interestingly and importantly, the body weight loss observed in the CIA rats was reversed by daily treatment with matrine at doses of 20, 40 and 80 mg/kg (p < 0.05, p < 0.01, and p < 0.01, respectively) (Figure 3).


Matrine Exerts a Strong Anti-Arthritic Effect on Type II Collagen-Induced Arthritis in Rats by Inhibiting Inflammatory Responses
Effects of matrine on arthritis score changes for the paw of CIA rats. Norm: normal rats; Cont: control rats; Dex: rats treated with dexamethasone. Data are presented as the mean ± SD (n = 10). * p < 0.05, ** p < 0.01, compared with Cont. (control). Day 0 in the figure is day 21 after initial immunization.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5037690&req=5

ijms-17-01410-f002: Effects of matrine on arthritis score changes for the paw of CIA rats. Norm: normal rats; Cont: control rats; Dex: rats treated with dexamethasone. Data are presented as the mean ± SD (n = 10). * p < 0.05, ** p < 0.01, compared with Cont. (control). Day 0 in the figure is day 21 after initial immunization.
Mentions: A type II collagen-induced arthritis (CIA) rat model was prepared to evaluate the therapeutic effects of matrine in rats with RA. As shown in Figure 1, Figure 2 and Figure 3, compared with the normal rats, significant RA symptoms were observed when the experimental rats were immunized with type II collagen (CII) twice, including paw swelling and erythema (p < 0.01), higher arthritis indices (p < 0.01) and obvious weight loss (p < 0.05). These symptoms significantly improved after treatment with dexamethasone. Our results indicate that starting on the 6th day after the initial dexamethasone administration (0.05 mg/kg), paw swelling was decreased in CIA rats compared with the control group (p < 0.01) (Figure 1). Additionally, the arthritis indices in the dexamethasone (0.05 mg/kg)-treated CIA rats were also significantly decreased compared with the control group (p < 0.01) (Figure 2). However, it was clear that the daily administration of dexamethasone (0.05 mg/kg) did not reverse the body weight loss observed in the CIA rats; instead, dexamethasone aggravated the weight loss (Figure 3). This effect might be associated with the inherent side effects of dexamethasone. Similar to the dexamethasone treatment, matrine significantly decreased paw swelling and arthritis indices when administered at doses of 40 (p < 0.05) and 80 mg/kg (p < 0.01), and matrine moderately decreased these symptoms when administered daily at a dose of 20 mg/kg (Figure 1 and Figure 2). Interestingly and importantly, the body weight loss observed in the CIA rats was reversed by daily treatment with matrine at doses of 20, 40 and 80 mg/kg (p < 0.05, p < 0.01, and p < 0.01, respectively) (Figure 3).

View Article: PubMed Central - PubMed

ABSTRACT

To investigate anti-arthritic effects of matrine isolated from the roots of S. flavescens on type II collagen-induced arthritis (CIA) in rats and to explore its related potential mechanisms, CIA rats were established and administered with matrine (20, 40 or 80 mg/kg/days, for 30 days). Subsequently, blood was collected to determine serum levels of TNF-&alpha;, IL-1&beta;, IL-6, IL-8, IL-17A, IL-10, MMP-2, MMP-3 and MMP-9, and hind paws and knee joints were collected for histopathological examination. Furthermore, indices of the thymus and spleen were determined, and synovial tissues were collected to determine the protein expressions of p-I&kappa;B, I&kappa;B, Cox-2 and iNOS. Our results indicated that matrine significantly suppressed inflammatory reactions and synovial tissue destruction. Matrine inhibited paw swelling, arthritis indices and weight loss in CIA rats. Additionally, matrine decreased the levels of TNF-&alpha;, IL-1&beta;, IL-6, IL-8, IL-17A, MMP-2, MMP-3 and MMP-9. Matrine also down-regulated expressions of p-I&kappa;B, Cox-2, and iNOS but up-regulated I&kappa;B in synovial tissues in CIA rats. The results suggested matrine possesses an anti-arthritic effect in CIA rats via inhibiting the release of pro-inflammatory cytokines and proteins that promote the NF-&kappa;B pathway.

No MeSH data available.


Related in: MedlinePlus